Monday, March 24, 2008

 

Here Come the Cannabinoid Blockers

Both the benefits and harms of potentially abused drugs occur because they mimic endogenous roll molecules, and we have receptors for those molecules.
As with opiates, humans make endogenous cannabinoids and have cannabinoid receptors — CB1 and CB2 (Journal Watcher May 17 2005).
In actinic ray of animal enquiry results indicating that the endocannabinoid grouping plays an important role in food ingestion and forcefulness construction, investigators asked whether blocking these receptors might aid system of measurement loss in humans.

A European team randomized 1507 obese subjects (body-mass indicator ≥30 kg/m2, or BMI >27 with dyslipidemia or hypertension) to handling with a CB1 medicine, rimonabant (high or low dose), or medicinal drug.
After 1 year, the high-dose building block weighed a mean of 10.5 pounds less than did the medication group; 51% vs. 19% had achieved at least a 5% sports equipment loss.
The high-dose unit also showed significant reductions in waistline borderline (and, hence, abdominal fat), triglyceride levels, insulin action, and metabolic symptom, as well as higher levels of HDL cholesterol.
Rates of adverse events, serious adverse events, and drug discontinuation were similar among groups.Report

This large cogitation, which lasted a year, is more impressive than the smaller and shorter studies of rimonabant that have been published previously.
Clinically important oppressiveness loss was sustained for at least 1 year — a higher-up solvent than those of most diet studies.
Moreover, no serious adverse effects were apparent.
Setup, given the happening with recent “wonder drugs,” some scepticism is warranted.
This is a part of article Here Come the Cannabinoid Blockers Taken from "Generic Acomplia (Rimonabant) Discussions" Information Blog

Labels:


Comments: Post a Comment



<< Home

This page is powered by Blogger. Isn't yours?